ArticleCase reports in oncology
Naproxen in High-Temperature Neoplastic Fever: A Case Report Highlighting Its Distinctive Profile among Nonsteroidal Anti-Inflammatory Drugs.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neoplastic fever (NF) is a relatively common yet frequently underrecognized complication in patients with advanced malignancies. NF is characterized by persistent low-grade fever (typically <38.5°C) driven by tumor-associated cytokine release rather than by infectious or autoimmune causes. As a leading contributor to fever of unknown origin in oncology patients, NF is often difficult to diagnose because of its nonspecific clinical presentation and reliance on exclusion criteria. This case illustrates the diagnostic complexity of NF and highlights the clinical value of targeted antipyretic strategies to support timely oncologic decision-making. Case Presentation: A 41-year-old male with stage IVC sigmoid colon adenocarcinoma presented with recurrent high-grade fever (up to 40.4°C), chills, and markedly elevated inflammatory markers (C-reactive protein [CRP]: 202.0 mg/L; procalcitonin: 3.44 ng/mL) over a 2-week period. Comprehensive infectious evaluations, including cultures, antigen testing, and imaging, were all negative. Empirical antibiotics and conventional nonsteroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, diclofenac) failed to achieve sustained defervescence. After ruling out infectious and autoimmune causes and considering chemotherapy-induced tumor lysis, NF was suspected. Administration of 500 mg of naproxen (suppository) led to rapid normalization of temperature (36.4°C) and sustained defervescence. A corresponding decrease in inflammatory markers (CRP: 51.6 mg/L; procalcitonin: 1.70 ng/mL) further confirmed the diagnosis. Conclusion: This case underscores the importance of NF in cancer patients with persistent high-grade fevers who are unresponsive to antimicrobial and standard antipyretic therapies and further demonstrates the distinctive efficacy of naproxen in managing such fevers compared with conventional NSAIDs. Specifically, the rapid and sustained defervescence observed following naproxen administration not only supported the diagnosis but also facilitated the timely continuation of anticancer treatment. Therefore, early recognition of NF and appropriate use of the naproxen test may help avoid unnecessary interventions and ultimately improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.